FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...
As GLP-1 competition shifts from molecules to prescriptions, manufacturers, pharmacies, providers, and payers are racing to ...
Pharmaceutical Executive: What are the costly ways that RWD can impact clinical trial recruitment? Jen Lamppa: Two things ...
Elaine Ferguson, global president at Inizio Medical, spoke with Pharmaceutical Executive about the importance of both managing and growing talent. In today’s world, this requires people already in ...
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon ...
On August 31, the Trump Administration expanded its Most-Favored-Nation (MFN) drug pricing initiative by securing agreements ...
Orbis Medicines announced a strategic collaboration and license agreement with Novo to discover and develop next-generation ...
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea ...
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, ...
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership ...
In a conversation with Pharmaceutical Executive, former U.S. Representative Joe Cunningham (D-SC), and spokesperson for the Pharmaceutical Reform Alliance, discussed the limitations of the new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results